Exclusive: TPG explores $3 billion sale of specialty drugmaker Aptalis

NEW YORK (Reuters) – TPG Capital LP has been exploring a sale of Aptalis Pharma, a specialty drugmaker it has owned since 2008 and values at more than $3 billion, four people familiar with the matter said on Wednesday.

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.